WO1997009334A1 - Method for the production of magnesium pyridoxal-5'-phosphate glutamate and intermediate products obtained thereby - Google Patents

Method for the production of magnesium pyridoxal-5'-phosphate glutamate and intermediate products obtained thereby Download PDF

Info

Publication number
WO1997009334A1
WO1997009334A1 PCT/EP1996/003749 EP9603749W WO9709334A1 WO 1997009334 A1 WO1997009334 A1 WO 1997009334A1 EP 9603749 W EP9603749 W EP 9603749W WO 9709334 A1 WO9709334 A1 WO 9709334A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridoxal
phosphate
phenetidyl
magnesium
under formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/003749
Other languages
French (fr)
Inventor
Panagiotis Maidonis
Werner Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Steigerwald Arzneimittelwerk GmbH
Original Assignee
Steigerwald Arzneimittelwerk GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steigerwald Arzneimittelwerk GmbH filed Critical Steigerwald Arzneimittelwerk GmbH
Priority to HK99100006.4A priority Critical patent/HK1014958B/en
Priority to DK96930965T priority patent/DK0861258T3/en
Priority to AU69845/96A priority patent/AU706162B2/en
Priority to DE69617261T priority patent/DE69617261T2/en
Priority to PL96325333A priority patent/PL325333A1/en
Priority to US09/029,426 priority patent/US5962687A/en
Priority to JP9510820A priority patent/JPH11512103A/en
Priority to EP96930965A priority patent/EP0861258B1/en
Priority to AT96930965T priority patent/ATE209210T1/en
Priority to NZ318374A priority patent/NZ318374A/en
Publication of WO1997009334A1 publication Critical patent/WO1997009334A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Definitions

  • the invention relates to the method for the production of magnesium pyridoxal-5' -phosphate glutamate.
  • the invention especially relates to a new method for the production of magnesium pyridoxal-5' -phosphate glutamate starting from an acid addition salt of pyridoxine, such as pyridoxine hydrochloride, in which pyridoxal-5' -phosphate is obtained as an intermediate product.
  • Magnesium pyridoxal-5' -phosphate glutamate is known from DE 24 61 742. In this publication, it is proposed as a medicament for prophylaxis and therapy of metabolic disturbances, especially for influencing the lipid and cholesterol state.
  • DE 40 16 963 relates to the use of magnesium pyridoxal-5' - phosphate glutamate for the reduction of LD -bound peroxides and for prevention of vascular damage.
  • an object of the invention is to provide a synthesis of this type.
  • the object is solved according to the invention by providing a synthesis for magnesium pyridoxal-5 1 -phosphate glutamate in which pyridoxal-5' -phosphate is obtained as an intermediate product.
  • the pyridoxal-5' -phosphate accumulates in the form of an aqueous solution from which the pyridoxal-5' -phosphate can be isolated if required.
  • the obtained pyridoxal- 5 ' -phosphate solution can also be reacted to the end product in an advantageous manner without isolation of the pyridoxal- 5' -phosphate.
  • the steps required according to the state of the art for purification and drying of the pyridoxal- 5' -phosphate are omitted.
  • a further point of the invention relates to the fact that, starting from pyridoxine, and especially an acid addition salt of pyridoxine, such as pyridoxine hydrochloride, pyridoxal-5* - phosphate is produced in a high yield according to a new method with p-phenetidyl pyridoxal and p-phenetidyl-pyridoxal- 5' -phosphate as intermediate products.
  • Subject matter of the invention is a method for the synthesis of magnesium pyridoxal-5* -phosphate glutamate which is characterised in that:
  • A) pyridoxine or an acid addition salt thereof is oxidised with manganese(IV) oxide to pyridoxal;
  • p-phenetidyl-pyridoxal is selectively phosphorylated on the 5' -hydroxymethyl group under formation of p-phenetidyl- pyridoxal-5' -phosphate;
  • p-phenetidyl-pyridoxal-5' -phosphate is hydrolysed under formation of an alkali metal salt of pyridoxal-5' - phosphate
  • In-process controls of this type can comprise analyses, such as HPLC analyses, which can be reliably carried out in a short amount of time (15 min) .
  • pyridoxine preferably in form of an acid addition salt such as pyridoxine hydrochloride (6)
  • a suitable oxidation agent is manganese(IV) oxide which is suitably used in activated form.
  • the oxidation is then preferably carried out in sulfuric acid solution under controlled pH and temperature conditions as well as under light exclusion.
  • the degree of reaction can be continuously examined by means of a suitable analytical system (for example, HPLC) . It is particularly preferred to stop the reaction as soon as the entire amount of pyridoxine was oxidised.
  • HPLC suitable analytical system
  • oxidation of a pyridoxine acid addition salt to pyridoxal (5) with manganese(IV) oxide is typically carried out in the acidic range without adherence to particular pH or temperature conditions.
  • oxidation with manganese(IV) oxide is carried out in a particularly advantageous manner at a constant pH value of 5,1 and a constant temperature of 14°C for further increasing the yield and minimising the amount of side products formed.
  • the reaction mixture can subsequently be subjected to processing for separation, for example by filtration, of precipitated material such as reacted or non-reacted oxidation agent, for example manganese salts.
  • precipitated material such as reacted or non-reacted oxidation agent, for example manganese salts.
  • non-reacted oxidation agent such as manganese(IV) oxide
  • Isolation of pyridoxal (5) can be carried out by the person skilled in the art according to new methods without difficulty.
  • isolation is not required and the obtained pyridoxal solution can be directly used as an aqueous pyridoxal solution in the next reaction step.
  • aqueous solution of pyridoxal (5) preferably relating to the reaction solution obtained in the oxidation, is brought to a weakly acidic pH value and preferably a pH value of 4.5. After that, p-phenetidine (7) is added preferably in slight excess. After conclusion of the reaction, the formed precipitate is separated (preferably filtered) , for example by washing with water and/or an organic solvent, purified, and preferably dried, whereby p-phenetidyl-pyridoxal (4) is obtained.
  • Excess p-phenetidine (7) can be recovered. If ions originating from the oxidation agent, such as manganese(II) ions, are contained in the solution obtained after the separation of the precipitate, these can also be recovered by precipitation with the aid of lye for example.
  • ions originating from the oxidation agent such as manganese(II) ions
  • the Schiff's base p-phenetidyl-pyridoxal (4) is subjected to a treatment for selective phosphorylation of the 5' - hydroxymethyl group under formation of p-phenetidyl-pyridoxal 5' -phosphate (3).
  • the phosphorylation occurs through treating p-phenetidyl-pyridoxal (4) with a suitable phosphorylation agent.
  • a suitable phosphorylation agent for example, reaction with polyphosphoric acid is suitable.
  • phosphorylation preferably occurs under controlled temperature conditions (4 to 25°C) as well as light exclusion.
  • controlled temperature conditions 4 to 25°C
  • the degree of reaction can be constantly examined by means of a suitable analytical system (for example, HPLC) . It is particularly preferred to stop the reaction as soon as the entire amount of p-phenetidyl-pyridoxal (4) is phosphorated.
  • polyphosphoric acid and p-phenetidyl-pyridoxal are used in the ratio of 4-6 parts to 1 part.
  • p-phenetidyl-pyridoxal-5' - polyphosphates form. Then, through the subsequent addition of water and acid, a partial hydrolysis occurs under formation and precipitation of p-phenetidyl-pyridoxal-5' -phosphate (3) . The precipitation can be promoted by addition of lye.
  • the compound obtained is purified in the customary manner, for example by washing with water and/or an organic solvent. It can be dried and isolated, but is suitably processed as a moist precipitate for the purpose of further synthesis.
  • the phosphate accumulating due to the excess of polyphosphate can be reacted with calcium hydroxide to calcium phosphate and can be optionally easily stored with low risk and/or further processed or disposed.
  • p-phenetidyl-pyridoxal-5' -phosphate (3) is then hydrolysed to pyridoxal 5' -phosphate (2) and p-phenetidine (7) by treatment with an aqueous alkali solution, preferably at a pH value of more than 12.5.
  • the formed p-phenetidine and the alkali metal salt of pyridoxal 5' -phosphate can be separated according to any suitable method, p-phenetidine (7) can be separated from the aqueous solution by extraction with a suitable organic solvent, for example an aliphatic or aromatic hydrocarbon such as toluol.
  • the p-phenetidine (7) can be separated according to a preferable embodiment by means of a liquid- liquid separator unit.
  • a separation of this type is more time-saving, more ecological, more efficient, easier and therewith more economic than the extraction.
  • the p-phenetidine (7) recovered in this reaction step can be purified by means of distillation for example and then newly used in the first reaction step.
  • the alkali metal salt of pyridoxal-5' -phosphate (2) can be precipitated from the obtained aqueous solution by concentration.
  • the precipitate can be further purified by washing or recrystallization for example.
  • the alkali metal ions must first be removed.
  • any suitable method can be employed.
  • the obtained aqueous alkali metal salt solution of pyridoxal- 5' -phosphate can be subjected to an ion exchange treatment.
  • the solution obtained thereby can - after optional concentration - be directly used for synthesis of magnesium pyridoxal-5 1 -phosphate glutamate (1).
  • an aqueous solution of previously isolated and purified pyridoxal -5' -phosphate (2) can be used in this case.
  • the aqueous solution of pyridoxal-5' -phosphate (2) is added to a solution which was obtained by reaction of a magnesium alkolholate with water and addition of glutamic acid (8) .
  • magnesium ethylate (9) is particularly preferred as a magnesium alcoholate because ethanol is then released by the reaction which does not encumber the pharmaceutical quality of the produced active ingredient with any undesired residues.
  • the mixture is then added to a suitable solvent, preferably ethanol.
  • the reaction is preferably carried out in the cold under air and light exclusion in as much as this is conducive to no side products forming.
  • Magnesium pyridoxal-5' -phosphate glutamate (l) can be separated from the suspension by filtration for example. The product obtained in this manner can be purified by washing and/or recrystallization and subsequently dried.
  • magnesium ethylate and ethanol By using magnesium ethylate and ethanol, a solution is obtained after separation of magnesium pyridoxal-5' -phosphate glutamate (1) which consists of water and ethanol.
  • the solution can be simply disposed of or can be separated by distillation into its components.
  • Shimadzu-unit comprising: LC-10AS liquid chromatograph; SIL-
  • Shimadzu-unit comprising: LC-10AS liquid chromatograph; SIL-
  • pyridoxine hydrochloride (6) 100 g pyridoxine hydrochloride (6) are dissolved in 1500 g water and adjusted to a pH of 5.10 with cold 4N sodium hydroxide solution. The obtained solution is brought to a temperature of 14°C and added to 75 g activated manganese(IV) oxide under strong stirring.
  • the reaction starts immediately after manganese dioxide addition and the pH value increases if it is not permanently adjusted.
  • the pH value of the reaction suspension is held constant at 5.10 ⁇ 0.10 by means of a constant pH constant holder under intensive stirring and temperature control (14 ⁇ 2°C) .
  • HPLC system 1 in the form of in-process controls. After approximately ten hours, the entire amount of pyridoxine hydrochloride was converted into pyridoxal. After that, the excess manganese dioxide - non-reacted and contaminated with pyridoxal - is filtered, washed three times with approximately 300 g deionized water and dried at 120°C.
  • the precipitate is suspended three times each in 700 g deionized water and filtered. Subsequently, it is suspended and filtered by means of an Ultra-Turax in 700 g n-heptane. The n-heptane filtrate is redistilled and the collected para- phenetidine residues are stored until conclusion of the third step.
  • the end of hydrolysis is brought about by rapid cooling of the reaction solution to 10°C. Thereby, the phosphorylated product begins to precipitate. Then, approximately 7500 g of 2N sodium hydroxide solution pre-cooled to approximately 10°C are slowly added under intense stirring and cooling until the pH value of the reaction suspension is 2.10. The orange-brown reaction product precipitated thereby is filtered well and washed three times each with approximately 500 g deionized water. The well filtered precipitate is directly used for the third step of the synthesis.
  • an organic-aqueous-separator for continuous operation can be used for the separation of para-phenetidine.
  • the collected para- phenetidine residues from the first and third steps can be purified by means of distillation and newly used.
  • the pyridoxal-5' -phosphate is present at the end of this separation operation as a sodium salt in the aqueous solution.
  • 800 ml cation exchanger for example Amperlite Type IR-120 (1.9 mVal/ml)
  • the sodium ion is removed from pyridoxal-5' -phosphate.
  • a pure aqueous solution of pyridoxal- 5' -phosphate is obtained.
  • 2500 ml eluate contain 57-63 g (78.6-86.9% theoretical yield) pyridoxal-5' -phosphate (2). This is concentrated under vacuum at max. 40°C to approximately 500 ml and used for MPPG production.
  • the Pyridoxal-5' -phosphate synthesised in this manner can also be isolated at this point (new synthesis of pyridoxal-5' - phosphate) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to a method for the production of magnesium pyridoxal-5'-phosphate glutamate, in which pyridoxine or an acid addition salt thereof is oxidised with manganese (IV) oxide to pyridoxal; pyridoxal is reacted with p-phenetidine under formation of the Schiff's base p-phenetidyl-pyridoxal; p-phenedityl-pyridoxal is selectively phosphorylated on the 5'-hydroxymethyl group under formation of p-phenetidyl-pyridoxal-5'-phosphate; p-phenetidyl-pyridoxal-5'-phosphate is hydrolysed under formation of an alkali metal salt of pyridoxal-5'-phosphate; the alkali metal ions are removed in order to obtain pyridoxal-5'-phosphate; pyridoxal-5'-phosphate is reacted with a reaction product of a magnesium alcoholate and L-glutamic acid; and the formed magnesium pyridoxal-5'-phosphate glutamate is isolated. Furthermore, the invention relates to intermediate products obtained with this method.

Description

Method for the production of magnesium pyridoxal-5'-phosphate glutamate and intermediate products obtained thereby.
The invention relates to the method for the production of magnesium pyridoxal-5' -phosphate glutamate. The invention especially relates to a new method for the production of magnesium pyridoxal-5' -phosphate glutamate starting from an acid addition salt of pyridoxine, such as pyridoxine hydrochloride, in which pyridoxal-5' -phosphate is obtained as an intermediate product.
Magnesium pyridoxal-5' -phosphate glutamate is known from DE 24 61 742. In this publication, it is proposed as a medicament for prophylaxis and therapy of metabolic disturbances, especially for influencing the lipid and cholesterol state. DE 40 16 963 relates to the use of magnesium pyridoxal-5' - phosphate glutamate for the reduction of LD -bound peroxides and for prevention of vascular damage.
Considering the importance of magnesium pyridoxal-5' -phosphate glutamate as a medicament, the need exists for a new, simpler and more economic synthesis for this substance. Therefore, an object of the invention is to provide a synthesis of this type.
The object is solved according to the invention by providing a synthesis for magnesium pyridoxal-51 -phosphate glutamate in which pyridoxal-5' -phosphate is obtained as an intermediate product. The pyridoxal-5' -phosphate accumulates in the form of an aqueous solution from which the pyridoxal-5' -phosphate can be isolated if required. However, the obtained pyridoxal- 5 ' -phosphate solution can also be reacted to the end product in an advantageous manner without isolation of the pyridoxal- 5' -phosphate. Therewith, the steps required according to the state of the art for purification and drying of the pyridoxal- 5' -phosphate are omitted. A further point of the invention relates to the fact that, starting from pyridoxine, and especially an acid addition salt of pyridoxine, such as pyridoxine hydrochloride, pyridoxal-5* - phosphate is produced in a high yield according to a new method with p-phenetidyl pyridoxal and p-phenetidyl-pyridoxal- 5' -phosphate as intermediate products.
Subject matter of the invention is a method for the synthesis of magnesium pyridoxal-5* -phosphate glutamate which is characterised in that:
A) pyridoxine or an acid addition salt thereof is oxidised with manganese(IV) oxide to pyridoxal;
B) pyridoxal is reacted with p-phenetidine under formation of the Schiff's base p-phenetidyl-pyridoxal;
C) p-phenetidyl-pyridoxal is selectively phosphorylated on the 5' -hydroxymethyl group under formation of p-phenetidyl- pyridoxal-5' -phosphate;
D) p-phenetidyl-pyridoxal-5' -phosphate is hydrolysed under formation of an alkali metal salt of pyridoxal-5' - phosphate;
E) the alkali metal ions are removed in order to obtain pyridoxal-5' -phosphate;
F) pyridoxal-5' -phosphate is reacted with a reaction product of a magnesium alcoholate and L-glutamic acid; and
G) the formed magnesium pyridoxal-5' -phosphate glutamate is isolated.
A preferred embodiment of the invention is represented in the following reaction scheme.
Figure imgf000005_0001
pyridoxine hydrochloride (6) pyridoxal (5) para-phenetidyl-pyridoxal (4)
L-glutamic acid (8)
Figure imgf000005_0002
Figure imgf000005_0003
para-phenetidyl- pyridoxal-5'-phosphate (3) magnesium glutamate (10) pyridoxal-5'-phosphate (2)
Figure imgf000005_0004
magnesium pyridoxal-5'-phosphate glutamate (I) Molecular weight of the compounds .
manganese ( IV) oxide MnO 86,9 g/mol para-p enetidine (7 ) CgH^NO 137,0 g/mol para-phenetidyl -pyridoxal < 4 > C16H18N2°3 286,0 g/mol para-phenetidyl -pyridoxal- 5 ' -phosphate ( 3 ) C16H19N206P 366,0 g/mol pyridoxal ( 5 ) C8H9N03 167,0 g/mol pyridoxal-5 ' -phosphate ( 2 ) C8H10NO6 P 247,0 g/mol pyridoxal-5 ' -phosphate monohydrate ( 2 ' ) C8H12 N07P 265,0 g/mol pyridoxine hydrochloride (6) C8H12 C1N03 205,5 g/mol magnesium pyridoxal-5' -phosphate glutamate (1) C3H11Mg2.5N2θ9P 432,0 g/mol magnesium pyridoxal - 5 ' -phosphate glutamate dihydrate (l,)C13H15Mg2.5N2011P 464,0 g/mol
It has been shown to be advantageous to carry out the individual synthesis steps discontinuously in suitable temperature and pH controlled units under light and/or air exclusion.
In order to be able to monitor the chemical reaction at any time, it is possible to carry out in-process controls for example. In-process controls of this type can comprise analyses, such as HPLC analyses, which can be reliably carried out in a short amount of time (15 min) .
Furthermore, it has been shown to be suitable to release the product of each step for further processing first after carrying out an analysis and a purity test.
The individual steps of the synthesis are illustrated in detail in the following.
According to the invention, pyridoxine, preferably in form of an acid addition salt such as pyridoxine hydrochloride (6) , is first oxidised to pyridoxal (5) . A suitable oxidation agent is manganese(IV) oxide which is suitably used in activated form. The oxidation is then preferably carried out in sulfuric acid solution under controlled pH and temperature conditions as well as under light exclusion. The degree of reaction can be continuously examined by means of a suitable analytical system (for example, HPLC) . It is particularly preferred to stop the reaction as soon as the entire amount of pyridoxine was oxidised. As opposed to known methods of oxidation of pyridoxine hydrochloride (6) , the amount of oxidation side products formed can be diminished and the yield of pyridoxal (5) can be increased thereby.
The described oxidation of a pyridoxine acid addition salt to pyridoxal (5) with manganese(IV) oxide is typically carried out in the acidic range without adherence to particular pH or temperature conditions. However, oxidation with manganese(IV) oxide is carried out in a particularly advantageous manner at a constant pH value of 5,1 and a constant temperature of 14°C for further increasing the yield and minimising the amount of side products formed.
The reaction mixture can subsequently be subjected to processing for separation, for example by filtration, of precipitated material such as reacted or non-reacted oxidation agent, for example manganese salts. Thereby, it is also possible to recover non-reacted oxidation agent, such as manganese(IV) oxide and newly add this later to the process.
Isolation of pyridoxal (5) can be carried out by the person skilled in the art according to new methods without difficulty.
However, according to the invention, isolation is not required and the obtained pyridoxal solution can be directly used as an aqueous pyridoxal solution in the next reaction step.
An aqueous solution of pyridoxal (5) , preferably relating to the reaction solution obtained in the oxidation, is brought to a weakly acidic pH value and preferably a pH value of 4.5. After that, p-phenetidine (7) is added preferably in slight excess. After conclusion of the reaction, the formed precipitate is separated (preferably filtered) , for example by washing with water and/or an organic solvent, purified, and preferably dried, whereby p-phenetidyl-pyridoxal (4) is obtained.
Excess p-phenetidine (7) can be recovered. If ions originating from the oxidation agent, such as manganese(II) ions, are contained in the solution obtained after the separation of the precipitate, these can also be recovered by precipitation with the aid of lye for example.
The Schiff's base p-phenetidyl-pyridoxal (4) is subjected to a treatment for selective phosphorylation of the 5' - hydroxymethyl group under formation of p-phenetidyl-pyridoxal 5' -phosphate (3). The phosphorylation occurs through treating p-phenetidyl-pyridoxal (4) with a suitable phosphorylation agent. For example, reaction with polyphosphoric acid is suitable.
In this case, phosphorylation preferably occurs under controlled temperature conditions (4 to 25°C) as well as light exclusion. For an optimal reaction course, it has been shown to be favourable to bring the dried p-phenetidyl-pyridoxal (4) to a particle size of < 500 μm before the reaction. Furthermore, it is advantageous to mix p-phenetidyl-pyridoxal (4) and polyphosphoric acid as intimately as possible for reaction, for example in a kneading unit. The degree of reaction can be constantly examined by means of a suitable analytical system (for example, HPLC) . It is particularly preferred to stop the reaction as soon as the entire amount of p-phenetidyl-pyridoxal (4) is phosphorated. According to a particularly preferred embodiment, polyphosphoric acid and p-phenetidyl-pyridoxal are used in the ratio of 4-6 parts to 1 part.
In the above described reaction, p-phenetidyl-pyridoxal-5' - polyphosphates form. Then, through the subsequent addition of water and acid, a partial hydrolysis occurs under formation and precipitation of p-phenetidyl-pyridoxal-5' -phosphate (3) . The precipitation can be promoted by addition of lye. The compound obtained is purified in the customary manner, for example by washing with water and/or an organic solvent. It can be dried and isolated, but is suitably processed as a moist precipitate for the purpose of further synthesis.
The phosphate accumulating due to the excess of polyphosphate can be reacted with calcium hydroxide to calcium phosphate and can be optionally easily stored with low risk and/or further processed or disposed.
p-phenetidyl-pyridoxal-5' -phosphate (3) is then hydrolysed to pyridoxal 5' -phosphate (2) and p-phenetidine (7) by treatment with an aqueous alkali solution, preferably at a pH value of more than 12.5. The formed p-phenetidine and the alkali metal salt of pyridoxal 5' -phosphate can be separated according to any suitable method, p-phenetidine (7) can be separated from the aqueous solution by extraction with a suitable organic solvent, for example an aliphatic or aromatic hydrocarbon such as toluol.
Alternatively, the p-phenetidine (7) can be separated according to a preferable embodiment by means of a liquid- liquid separator unit. A separation of this type is more time-saving, more ecological, more efficient, easier and therewith more economic than the extraction. The p-phenetidine (7) recovered in this reaction step can be purified by means of distillation for example and then newly used in the first reaction step.
The alkali metal salt of pyridoxal-5' -phosphate (2) can be precipitated from the obtained aqueous solution by concentration. The precipitate can be further purified by washing or recrystallization for example.
In order to produce magnesium pyridoxal-5' -phosphate glutamate (1) from the alkali metal salt of pyridoxal-5' -phosphate (2), the alkali metal ions must first be removed. For this purpose, any suitable method can be employed. For example, the obtained aqueous alkali metal salt solution of pyridoxal- 5' -phosphate can be subjected to an ion exchange treatment. The solution obtained thereby can - after optional concentration - be directly used for synthesis of magnesium pyridoxal-51 -phosphate glutamate (1). It is also possible to isolate free pyridoxal-5' -phosphate (2) from the aqueous solution and to purify the compound according to customary methods known to the person skilled in the art. For the next synthesis step, an aqueous solution of previously isolated and purified pyridoxal -5' -phosphate (2) can be used in this case.
The aqueous solution of pyridoxal-5' -phosphate (2) is added to a solution which was obtained by reaction of a magnesium alkolholate with water and addition of glutamic acid (8) . magnesium ethylate (9) is particularly preferred as a magnesium alcoholate because ethanol is then released by the reaction which does not encumber the pharmaceutical quality of the produced active ingredient with any undesired residues. The mixture is then added to a suitable solvent, preferably ethanol. The reaction is preferably carried out in the cold under air and light exclusion in as much as this is conducive to no side products forming. Magnesium pyridoxal-5' -phosphate glutamate (l) can be separated from the suspension by filtration for example. The product obtained in this manner can be purified by washing and/or recrystallization and subsequently dried.
By using magnesium ethylate and ethanol, a solution is obtained after separation of magnesium pyridoxal-5' -phosphate glutamate (1) which consists of water and ethanol. The solution can be simply disposed of or can be separated by distillation into its components.
In the following, the invention is illustrated further by an example. In this example, the synthesis of magnesium pyridoxal-5' -phosphate glutamate (1) occurs with the aid of the following equipment:
a) temperature controlled mixing vessel (0 to 100°C) with pH monitoring and metering unit; b) temperature controlled kneading unit (0 to 100°C) with strong gearing in the low rotational speed range; c) extraction unit (aqueous/organic) and/or liquid-liquid separator; d) cation exchanger unit; e) filtration unit and/or solid-liquid separator; and f) drying unit.
HPLC analyses were conducted under the following conditions:
HPLC conditions
1. System a) chromatographic system:
Shimadzu-unit comprising: LC-10AS liquid chromatograph; SIL-
10A Auto Injector; SPD-10AV (UV-VIS; spectrophotometric detector) ; CBM-10A Communications Bus Module; CLASS-LC10
Software; PC 486, 40 Mhz; Desk Jet 560 C Hewlett Packard.
Stationary phase (column) Hypersil ODS 5μm 250x4.6 mm with pre-column cartridge 20x4.6 mm Mobile phase (eluent) aqueous 0.001 m KH2PO4 solution with H3PO4 adjusted to pH=3.
flow 1.5 ml/min injection 5 μl detection 295 nm analytical time 15 min
b) preparation: a small (for example drop-size) residual amount of a similar size as possible from the reaction mixture (for example two drops with liquid) is dissolved in five drops 10% sulfuric acid.
HPLC conditions
2. System a) chromatographic system:
Shimadzu-unit comprising: LC-10AS liquid chromatograph; SIL-
10A Auto Injector; SPD-10AV (UV-VIS; spectrophotometric detector) ; CBM-10A Communications Bus Module; CLASS-LC10
Software; PC 486, 40 Mhz; Desk Jet 560 C Hewlett Packard.
Stationary phase (column) Hypersil ODS 5μm 250x4.6 mm with pre-column cartridge 20x4.6 mm
Mobile phase (eluent) : 5% B
A ≡ aqueous 0.001 M KH2PO4 solution with H3PO4 adjusted to pH=3.
B ≡ acentonitrile
flow 1.5 ml/min injection 5 μl detection 295 nm analytical time 10 min b) preparation: a small (for example drop-size) residual amount of a similar size as possible from the reaction mixture (for example two drops with liquid) is dissolved in five drops 10% sulfuric acid.
Production example
lst Step
Production of p-phenetidyl-pyridoxal (4) from pyridoxine hydrochloride (6) .
100 g pyridoxine hydrochloride (6) are dissolved in 1500 g water and adjusted to a pH of 5.10 with cold 4N sodium hydroxide solution. The obtained solution is brought to a temperature of 14°C and added to 75 g activated manganese(IV) oxide under strong stirring.
The reaction starts immediately after manganese dioxide addition and the pH value increases if it is not permanently adjusted. Through addition of 10% sulfuric acid in portions, the pH value of the reaction suspension is held constant at 5.10 ± 0.10 by means of a constant pH constant holder under intensive stirring and temperature control (14 ± 2°C) . The course of the reaction is followed by means of HPLC (system 1) in the form of in-process controls. After approximately ten hours, the entire amount of pyridoxine hydrochloride was converted into pyridoxal. After that, the excess manganese dioxide - non-reacted and contaminated with pyridoxal - is filtered, washed three times with approximately 300 g deionized water and dried at 120°C. 25 g of manganese dioxide is recovered which can be used again. The combined aqueous solutions are first subjected to a membrane filtration (0.8 μm) and then adjusted to pH 4.5 with 10% sulfuric acid. Then, 80 g freshly distilled para-phenetidine is added in a portion to the pyridoxal solution under very intensive stirring. Thereby, the pH value of the reaction mixture increases to about 4.7 and the reaction product abruptly precipitates. This is further stirred for half an hour and subsequently filtered. The para-phenetidine containing therein is recovered by means of a liquid-liquid separator from the filtrate which is to be disposed.
The precipitate is suspended three times each in 700 g deionized water and filtered. Subsequently, it is suspended and filtered by means of an Ultra-Turax in 700 g n-heptane. The n-heptane filtrate is redistilled and the collected para- phenetidine residues are stored until conclusion of the third step.
The residue obtained in this manner is dried at 120°C and sifted to a particle size of < 500 μm. 124.8g (≡ 89.7% theoretical yield) of a fine, very light orange-yellow powder of para-phenetidyl-pyridoxal (4) is obtained.
2nd Step
Production of para-phenetidyl-pyridoxal-5' -phosphate (3) from para-phenetidyl-pyridoxal (4) .
1000 g of Polyphosphoric acid are placed into a temperature controlled kneading unit and cooled to 10°C. 250 g para- phenetidyl-pyridoxal (4) are slowly applied in small portions to the Polyphosphoric acid under intensive cooling. The Schiff's base of the pyridoxal slowly dissolves in the phosphorylation reagent under red coloration. The reaction heat formed thereby must be intensively carried off in such a manner that the temperature of the reaction mixture does not exceed 25°C. A temperature increase to about the double of this leads to approximately 20^ additional loss of yield. After the entire para-phenetidyl-pyridoxal mass was applied, the reaction mixture is further stirred under intensive cooling (< 25°C) overnight. On the following day, no more para-phenetidyl-pyridoxal is to be identified by means of an in-process control with the aid of HPLC (system 1) . The phosphorylation step is concluded therewith. Subsequently, approximately 2125 g ice are added into the mixing chamber and the reaction suspension is stirred further under intensive cooling for three hours. A homogeneous mustard-coloured mass forms while doing so. It is slowly added to 75 g 95-97% cold sulfuric acid, homogenised and heated for approximately 30 min at 80°C, wherein the polyphosphates are hydrolysed. The hydrolysis is followed by means HPLC (system 2) , whereby the exact moment of the stop of hydrolysis is recognised (based on the complete disappearance of the Polyphosphate peak) . The end of hydrolysis is brought about by rapid cooling of the reaction solution to 10°C. Thereby, the phosphorylated product begins to precipitate. Then, approximately 7500 g of 2N sodium hydroxide solution pre-cooled to approximately 10°C are slowly added under intense stirring and cooling until the pH value of the reaction suspension is 2.10. The orange-brown reaction product precipitated thereby is filtered well and washed three times each with approximately 500 g deionized water. The well filtered precipitate is directly used for the third step of the synthesis.
Nevertheless, should the product of this step be dried, this can occur at 105°C. 263.4 g (≡ 82.3% theoretical yield) of an orange-brown fine powder of para-phenetidyl-pyridoxal-5' - phosphate (3) would be obtained.
3rd Step
Production of pyridoxal-5'-phosphate (2) from para-phenetidyl- pyridoxal-5• -phosphate (3).
100 g and/or the corresponding amount of the moist precipitate of para-phenetidyl-pyridoxal- 5' -phosphate (3) obtained in the second step are added to 700 g 2N sodium hydroxide solution. The Schiff's base is hydrolysed to pyridoxal-5' -phosphate and para-phenetidyl at pH > 12.5. In the case that the above given amount of lye is not sufficient in order to obtain a pH > 12.5 - on account of the moist precipitate - the necessary amount of additional 2N sodium hydroxide solution is used. By extracting three times each with 300 g toluol, the para- phenetidine is removed from the solution. The toluol solution is redistilled. As an alternative to toluol extraction, an organic-aqueous-separator for continuous operation can be used for the separation of para-phenetidine. The collected para- phenetidine residues from the first and third steps can be purified by means of distillation and newly used.
The pyridoxal-5' -phosphate is present at the end of this separation operation as a sodium salt in the aqueous solution. By means of 800 ml cation exchanger, for example Amperlite Type IR-120 (1.9 mVal/ml) , the sodium ion is removed from pyridoxal-5' -phosphate. A pure aqueous solution of pyridoxal- 5' -phosphate is obtained. 2500 ml eluate contain 57-63 g (78.6-86.9% theoretical yield) pyridoxal-5' -phosphate (2). This is concentrated under vacuum at max. 40°C to approximately 500 ml and used for MPPG production. The Pyridoxal-5' -phosphate synthesised in this manner can also be isolated at this point (new synthesis of pyridoxal-5' - phosphate) .
4th Step
Production of magnesium pyridoxal-5' -phosphate glutamate (1) from pyridoxal-5' -phosphate (2).
540 g deionized water are placed into a reaction vessel and cooled to 0-3°C. Under nitrogen atmosphere and light exclusion, 62.58 g magnesium ethylate (9) are added and brought into solution by stirring. Thereby, the temperature increases to approximately 10°C. This is cooled to 3°C, 31.85 g glutamic acid (8) are added, and this is stirred for a further 10 min. Then, 500 ml pyridoxal-5' -phosphate solution of the third step (≡ 11.6% solution) is added in small portions within 60-90 min. to the magnesium glutamate solution just produced. Thereby, attention is paid that the pH value of the -solution remains within the range 8-9. Subsequently, this is further stirred for 3-5 hours and the resulting solution is filtered.
2000 ml ethanol is placed into a mixing vessel and cooled to 0°C under nitrogen atmosphere and light exclusion. Subsequently, the solution produced above is added drop-wise under stirring. The suspension attained in this manner is further stirred for approximately 15 hours, then filtered, and washed with a total of 200 ml ethanol. After that, the entire product is suspended in approximately 100 ml ethanol and newly filtered. The ethanol-moist product is dried in a drying cabinet at max. 60°C. 94.5-99.5 g (94-99% theoretical yield) of magnesium pyridoxal-5' -phosphate glutamate (1) is obtained.

Claims

Claims
1. A method for the production of magnesium pyridoxal-5' - phosphate glutamate, characterised in that,
A) pyridoxine or an acid addition salt thereof is oxidised with manganese(IV) oxide to pyridoxal;
B) pyridoxal is reacted with p-phenetidine under formation of the Schiff's base p-phenetidyl-pyridoxal;
C) p-phenetidyl-pyridoxal is selectively phosphorylated on the 5' -hydroxymethyl group under formation of p- phenetidyl-pyridoxal-5' -phosphate;
D) p-phenetidyl-pyridoxal-5' -phosphate is hydrolysed under formation of an alkali metal salt of pyridoxal-5' - phosphate;
E) the alkali metal ions are removed in order to obtain pyridoxal-5' -phosphate;
F) pyridoxal-5' -phosphate is reacted with a reaction product of a magnesium alcoholate and L-glutamic acid; and
G) the formed magnesium pyridoxal-51 -phosphate glutamate is isolated.
2. A method according to claim 1, characterised in that pyridoxine hydrochloride is used in step A.
3. A method according to claim l or 2, characterised in that the oxidation in step A is carried out with activated manganese(IV) oxide in sulfuric acid solution at a pH value of 5.1 and a constant temperature of 14°C.
4. Method according to one of the claims 1 to 3, characterised in that the pyridoxal containing reaction solution of the oxidation is used in step B.
5. Method according to one of the claims 1 to 4, characterised in that the phosphorylation in step C is carried out by reaction of p-phenetidyl-pyridoxal with polyphosphoric acid.
6. Method according to claim 5, characterised in that polyphosphoric acid and p-phenetidyl-pyridoxal are used in the ratio 4 parts to 1 part.
7. Method according to one of the claims 1 to 6, characterised in that the hydrolysis in step D occurs by means of a alkali hydroxide solution.
8. Method according to one of the claims 1 to 7, characterised in that the removal of the alkali metal ions in step E occurs by means of an ion exchanger.
9. Method according to one of the claims 1 to 8, characterised in that magnesium ethylate is used as a magnesium alcoholate in step F.
10. p-phenetidyl-pyridoxal.
11. p-phenetidyl-pyridoxal-5' -phosphate.
12. Method for the production of pyridoxal-5' -phosphate, characterised in that:
A) pyridoxine or an acid addition salt thereof is oxidised with manganese(IV) oxide to pyridoxal;
B) pyridoxal is reacted with p-phenetidine under formation of the Schiff's base p-phenetidyl-pyridoxal; C) p-phenetidyl-pyridoxal is selectively phosphorylated on the 5' -hydroxymethyl group under formation of p- phenetidyl-pyridoxal-5' -phosphate;
D) p-phenetidyl-pyridoxal-5'-phosphate is hydrolysed under formation of an alkali metal salt of pyridoxal-5' - phosphate;
E) the alkali metal ions are removed in order to obtain pyridoxal-5* -phosphate;
F) the pyridoxal-5'-phosphate obtained in step E is optionally isolated and dried.
PCT/EP1996/003749 1995-09-04 1996-08-26 Method for the production of magnesium pyridoxal-5'-phosphate glutamate and intermediate products obtained thereby Ceased WO1997009334A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
HK99100006.4A HK1014958B (en) 1995-09-04 1996-08-26 Method for the production of magnesium pyridoxal-5'-phosphate glutamate and intermediated products obtained thereby
DK96930965T DK0861258T3 (en) 1995-09-04 1996-08-26 Process for the preparation of magnesium pyridoxal-5'-phosphate glutamate and intermediates obtained thereby
AU69845/96A AU706162B2 (en) 1995-09-04 1996-08-26 Method for the production of magnesium pyridoxal-5'- phosphate glutamate and intermediate products obtained thereby
DE69617261T DE69617261T2 (en) 1995-09-04 1996-08-26 METHOD FOR PRODUCING MAGNESIUM PYRIDOXAL-5'-PHOSPHORIC ACID ESTER GLUTAMINATE AND INTERMEDIATE PRODUCTS PRODUCED THEREOF
PL96325333A PL325333A1 (en) 1995-09-04 1996-08-26 Method of obtaining 5'-phosphate-pyridoxal magnesium glutamate and respective intermediate products
US09/029,426 US5962687A (en) 1995-09-04 1996-08-26 Method for the production of magnesium pyridoxal-5'-phosphate glutamate and intermediate products obtained thereby
JP9510820A JPH11512103A (en) 1995-09-04 1996-08-26 Process for producing pyridoxal-5'-magnesium phosphate glutamate and intermediate obtained thereby
EP96930965A EP0861258B1 (en) 1995-09-04 1996-08-26 Method for the production of magnesium pyridoxal-5'-phosphate glutamate and intermediate products obtained thereby
AT96930965T ATE209210T1 (en) 1995-09-04 1996-08-26 METHOD FOR PRODUCING MAGNESIUM PYRIDOXAL-5'-PHOSPHORIC ACID ESTER GLUTAMInate AND INTERMEDIATE PRODUCTS PRODUCED THEREFROM
NZ318374A NZ318374A (en) 1995-09-04 1996-08-26 Method for the production of magnesium pyridoxal-5'-phosphate glutamate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19532625.3 1995-09-04
DE19532625A DE19532625C2 (en) 1995-09-04 1995-09-04 Process for the preparation of magnesium pyridoxal-5'-phosphate glutamate and intermediates obtained thereby

Publications (1)

Publication Number Publication Date
WO1997009334A1 true WO1997009334A1 (en) 1997-03-13

Family

ID=7771233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003749 Ceased WO1997009334A1 (en) 1995-09-04 1996-08-26 Method for the production of magnesium pyridoxal-5'-phosphate glutamate and intermediate products obtained thereby

Country Status (24)

Country Link
US (1) US5962687A (en)
EP (1) EP0861258B1 (en)
JP (1) JPH11512103A (en)
KR (1) KR19990044359A (en)
CN (1) CN1199402A (en)
AR (1) AR003488A1 (en)
AT (1) ATE209210T1 (en)
AU (1) AU706162B2 (en)
BA (1) BA96127A (en)
CA (1) CA2230555A1 (en)
CO (1) CO4750659A1 (en)
CZ (1) CZ292662B6 (en)
DE (2) DE19532625C2 (en)
DK (1) DK0861258T3 (en)
EG (1) EG20974A (en)
ES (1) ES2165521T3 (en)
HR (1) HRP960401B1 (en)
HU (1) HUP9802778A3 (en)
JO (1) JO1921B1 (en)
NZ (1) NZ318374A (en)
PL (1) PL325333A1 (en)
PT (1) PT861258E (en)
TW (1) TW442472B (en)
WO (1) WO1997009334A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090674A2 (en) * 2002-04-23 2003-11-06 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
KR101678865B1 (en) * 2007-12-14 2016-11-23 플레드파르마 에이비 Compounds for use in the treatment of cancer
CN106946932A (en) * 2017-03-21 2017-07-14 上海津力生物科技股份有限公司 A kind of preparation method of the phosphate of pyridoxal 5
CN108976259A (en) * 2017-06-01 2018-12-11 上海凯赛生物技术研发中心有限公司 A kind of synthetic method of phosphopyridoxal pyridoxal phosphate
CN107652323A (en) * 2017-09-20 2018-02-02 精晶药业股份有限公司 A kind of synthetic method of phosphopyridoxal pyridoxal phosphate
CN108754160B (en) * 2018-07-26 2020-05-08 江苏理工学院 Method for recycling manganese-containing pyridoxal wastewater
CN110016049A (en) * 2019-03-18 2019-07-16 武汉工程大学 A kind of preparation method of phosphopyridoxal pyridoxal phosphate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663557A (en) * 1966-06-08 1972-05-16 Kogerim Ets Biologically active forms of pyridoxine coenzymes
ES421396A3 (en) * 1973-12-12 1976-04-16 Vila Busquets Procedure for the manufacture of piridoxal phosphate. (Machine-translation by Google Translate, not legally binding)
DE2461742A1 (en) * 1974-12-28 1976-07-08 Steigerwald Arzneimittelwerk PYRIDOXIN DERIVATIVES AND THEIR PRODUCTION AND USE
DE4016963A1 (en) * 1990-05-25 1991-11-28 Steigerwald Arzneimittelwerk USE OF MAGNESIUM PYRIDOXAL 5'-PHOSPHATE GLUTAMINATE TO PREVENT ILLNESSES ARISING AS A RESULT OF DISSOLUTION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854559A (en) * 1973-10-01 1974-12-17 Deere & Co Control system for a hydraulically-operable brake and transmission

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663557A (en) * 1966-06-08 1972-05-16 Kogerim Ets Biologically active forms of pyridoxine coenzymes
ES421396A3 (en) * 1973-12-12 1976-04-16 Vila Busquets Procedure for the manufacture of piridoxal phosphate. (Machine-translation by Google Translate, not legally binding)
DE2461742A1 (en) * 1974-12-28 1976-07-08 Steigerwald Arzneimittelwerk PYRIDOXIN DERIVATIVES AND THEIR PRODUCTION AND USE
DE4016963A1 (en) * 1990-05-25 1991-11-28 Steigerwald Arzneimittelwerk USE OF MAGNESIUM PYRIDOXAL 5'-PHOSPHATE GLUTAMINATE TO PREVENT ILLNESSES ARISING AS A RESULT OF DISSOLUTION

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 067, no. 17, 23 October 1967, Columbus, Ohio, US; abstract no. 082109, MURAKAMI M ET AL: "Schiff base of pyridoxal phosphate" XP002020053 *
CHEMICAL ABSTRACTS, vol. 086, no. 3, 17 January 1977, Columbus, Ohio, US; abstract no. 016550, VILA BUSQUETS P: "Pyridoxal phosphate" XP002020054 *
CHEMICAL ABSTRACTS, vol. 101, no. 1, 2 July 1984, Columbus, Ohio, US; abstract no. 007040, MONTORO F ET AL: "Pyridoxal-5'-phosphate" XP002020052 *
IWANAMI M ET AL: "A new synthesis of pyridoxal 5-phosphate", BULL. CHEM. SOC. JAP. (BCSJA8);68; VOL.41 (1); PP.161-5, YAMANOUCHI PHARM. CO., LTD.;TOKYO; JAPAN, XP002020051 *

Also Published As

Publication number Publication date
KR19990044359A (en) 1999-06-25
JO1921B1 (en) 1997-01-15
ES2165521T3 (en) 2002-03-16
JPH11512103A (en) 1999-10-19
CA2230555A1 (en) 1997-03-13
BA96127A (en) 1998-12-28
HRP960401A2 (en) 1998-02-28
US5962687A (en) 1999-10-05
PT861258E (en) 2002-05-31
HUP9802778A2 (en) 1999-09-28
EP0861258B1 (en) 2001-11-21
EP0861258A1 (en) 1998-09-02
ATE209210T1 (en) 2001-12-15
AU706162B2 (en) 1999-06-10
TW442472B (en) 2001-06-23
HUP9802778A3 (en) 2001-02-28
DK0861258T3 (en) 2002-05-21
EG20974A (en) 2000-08-30
PL325333A1 (en) 1998-07-20
CZ59198A3 (en) 1998-07-15
CN1199402A (en) 1998-11-18
AU6984596A (en) 1997-03-27
NZ318374A (en) 1999-06-29
DE19532625C2 (en) 2000-04-20
CO4750659A1 (en) 1999-03-31
HK1014958A1 (en) 1999-10-08
AR003488A1 (en) 1998-08-05
DE19532625A1 (en) 1997-03-06
DE69617261T2 (en) 2002-05-08
DE69617261D1 (en) 2002-01-03
CZ292662B6 (en) 2003-11-12
HRP960401B1 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
US5962687A (en) Method for the production of magnesium pyridoxal-5&#39;-phosphate glutamate and intermediate products obtained thereby
US6121464A (en) Preparation of salts of ascorbyl 2-phosphoric esters
JPH031957B2 (en)
IE66570B1 (en) Process for separating 2-keto-L-gulonic acid from a fermented medium
CA1056383A (en) Process for producing nicotinic amide
HU226597B1 (en) Process for the preparation of a clavulanic acid potassium salt
HK1014958B (en) Method for the production of magnesium pyridoxal-5&#39;-phosphate glutamate and intermediated products obtained thereby
Boyer et al. Preparation of picryl chloride
CN106478722A (en) High-purity L ascorbic acid 2 magnesium phosphorate salt production process
JPH03204891A (en) Production of ascorbic acid-2-phosphoric acid ester
JPH04279593A (en) Process for preparing potassium magnesium l-ascorbate 2-phosphate
CN103172661A (en) Preparation method of phosphocreatine disodium salt
JPS5917104B2 (en) Method for producing hydroxyphenylglycine compounds
EP1059298B1 (en) Process for purifying L-ascorbyl 2-monophosphate
CN111875556A (en) Preparation method and system for ATC (alpha-amino-butyric acid) as important precursor in enzymatic production of L-cysteine
SU1018951A1 (en) Process for isolating and purifying sodium d-glucouronate and/or sodium 1,2-0-isopropylidene-d-glucouronate from mixtures also containing inorganic salts and/or carbonaceous impurities
JPS6377890A (en) Purifying method for l-ascorbic acid-2-phosphate
CN106397486A (en) Preparation method of high purity L-ascorbic acid-2-sodium phosphate
USRE28203E (en) Process of producing citric acid
CN119059501A (en) A method for preparing monocalcium phosphate using calcium phytate
SU1594179A1 (en) Method of producing thiaminstriphosphate
EP1072605B1 (en) Process for producing ascorbic acid-2-phosphoric ester salts
CN118724677A (en) An improved method for refining inositol
FI62541B (en) NOW FOERFARANDE FOER ATT SELECTIVE FRAMSTAELLA ESTRIOL-16ALFA17BETA-DIHEMISUCCINAT
CN115677769A (en) A kind of synthetic method suitable for industrialized production of benfotiamine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96197528.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2230555

Country of ref document: CA

Ref document number: 2230555

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 318374

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1998-591

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019980701601

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1997 510820

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996930965

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09029426

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-591

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1996930965

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980701601

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996930965

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019980701601

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1998-591

Country of ref document: CZ